Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

被引：0
|
作者：
Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
机构：
[1] Iran University of Medical Science (IUMS),Endocrine Research Center, Institute of Endocrinology and Metabolism
[2] Iran University of Medical Sciences (IUMS),Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism
来源：
BMC Cancer | / 21卷
关键词：
Peptide receptor radionuclide therapy; Radioiodine refractory-differentiated thyroid Cancer; Medullary thyroid carcinoma; Papillary thyroid carcinoma; Yttrium-90; 177Lu-DOTATATE; Indium-111; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
  • [2] Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity
    Rafał Czepczyński
    Magdalena Matysiak-Grześ
    Maria Gryczyńska
    Maciej Bączyk
    Anna Wyszomirska
    Marek Stajgis
    Marek Ruchała
    Archivum Immunologiae et Therapiae Experimentalis, 2015, 63 : 147 - 154
  • [3] Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity
    Czepczynski, Rafal
    Matysiak-Grzes, Magdalena
    Gryczynska, Maria
    Baczyk, Maciej
    Wyszomirska, Anna
    Stajgis, Marek
    Ruchala, Marek
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (02) : 147 - 154
  • [4] Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer Efficacy, Safety, and Survival Predictors
    Liu, Qingxing
    Kulkarni, Harshad R.
    Zhao, Tianzhi
    Schuchardt, Christiane
    Chen, Xiaoyuan
    Zhu, Zhaohui
    Zhang, Jingjing
    Baum, Richard P.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (03) : 221 - 227
  • [5] Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?
    Vaisman, Fernanda
    Rosado de Castro, Paulo Henrique
    Proenca Lobo Lopes, Flavia Paiva
    Kendler, Daniel Barretto
    Pessoa, Cencita H. N.
    Bulzico, Daniel Alves
    Leal, Douglas de Carvalho
    Vilhena, Bruno
    Vaisman, Mario
    Carneiro, Michel
    Corbo, Rossana
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (02) : 123 - 127
  • [6] Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
    Feng, Guoli
    Luo, Yi
    Zhang, Qi
    Zeng, Feng
    Xu, Jie
    Zhu, Jingqiang
    ENDOCRINE, 2020, 68 (01) : 56 - 63
  • [7] Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
    Guoli Feng
    Yi Luo
    Qi Zhang
    Feng Zeng
    Jie Xu
    Jingqiang Zhu
    Endocrine, 2020, 68 : 56 - 63
  • [8] Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials
    Su, Jingyang
    Wang, Menglei
    Fu, Yue
    Yan, Jiang
    Shen, Yuezhong
    Jiang, Jing
    Wang, Jue
    Lu, Jinhua
    Zhong, Yazhen
    Lin, Xianlei
    Lin, Zechen
    Lin, Shengyou
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (09) : 999 - 1008
  • [9] Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib
    Kawalec, Pawel
    Malinowska-Lipien, Iwona
    Brzostek, Tomasz
    Kozka, Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1303 - 1309
  • [10] Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer A Meta-analysis
    Lee, Dong Yun
    Kim, Yong-il
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (08) : 604 - 610
12345